Business Context and Reporting Period
This Form 8-K Current Report from Actinium Pharmaceuticals, Inc. (ATNM) covers events occurring on August 10, 2020. The filing details the implementation of a reverse stock split previously authorized by stockholders at the December 18, 2019 Annual Meeting.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-30 reverse stock split of issued and outstanding common stock.
- Effective Date: The split became effective at 5:00 p.m. Eastern Time on August 10, 2020.
- Trading Adjustment: Common stock began trading on a split-adjusted basis on August 11, 2020, under the symbol "ATNM" on the NYSE American.
- Security Adjustments: Options, warrants, and other rights to acquire common stock were proportionately adjusted (decreased share count, increased exercise price). Future grant limits under stock plans were also decreased proportionately.
- Fractional Shares: No fractional shares were issued. Stockholders entitled to fractions received cash payments based on the closing price on the last trading day prior to the Effective Time.
- CUSIP Update: The new CUSIP number for the common stock is 00507W206.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the operational details of the stock split. The primary contingency addressed is the handling of fractional shares via cash payment rather than issuance.
Investor Verification Checklist
- Verify the new CUSIP number (00507W206) for trading and record-keeping purposes.
- Confirm the adjusted number of shares held and the adjusted exercise prices for any outstanding options or warrants.
- Check for cash payments received in lieu of fractional shares if the pre-split share count was not evenly divisible by 30.
- Review the definitive proxy statement filed on November 25, 2019, for the full background of the authorization.